UnknownNot Applicable

Non Exudative AMD Imaged With SS-OCT

United States, Australia225 participantsStarted 2018-01-18

Plain-language summary

The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 50 and over
✓. Clinic diagnosis of non-exudative iAMD in at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02 mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR Clinical diagnosis of early or early/intermediate stage AMD in one eye in the absence of nGA or GA and exudative AMD in the other eye OR clinical diagnosis of GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye which has never been treated with anti-VEGF agents
✓. Willing and able to comply with clinic visits and study-related procedures
✓. Provide signed informed consent

Exclusion criteria

✕. Below the age of 50
✕. Subjects with exudative AMD in both eyes
✕. Eyes with evidence of non-proliferative and proliferative diabetic retinopathy.
✕. Presence of confounding ocular diagnosis such as myopia \>6D, or other ocular conditions that may cause retinal pigment epithelium atrophy or exudative MNV
✕. Subjects unable to give informed consent.
✕. Subjects who are unable to comply with imaging guidelines

What they're measuring

Change in Choroidal Perfusion Deficits at 1 year compared to Baseline

Timeframe: 1 year time point

Trial details

NCT IDNCT03688243

SponsorBoston Image Reading Center

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-03

View on ClinicalTrials.gov More Dry Macular Degeneration trials